Results 191 to 200 of about 257,064 (304)

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao   +27 more
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

Platelet miRNAs: differential expression in coronary artery disease and associations with course of left ventricular systolic function. [PDF]

open access: yesBMC Cardiovasc Disord, 2023
Goldschmied A   +7 more
europepmc   +1 more source

P4.24 COMPLIANCE AND DISTENSIBILITY OF DIFFERENT SEGMENTS OF AORTA AND RELATIONSHIPS BETWEEN AORTA DISTENSIBILITY AND SYSTOLIC AND DIASTOLIC FUNCTIONS OF THE LEFT VENTRICULAR

open access: hybrid, 2012
E.N. Borskaya   +7 more
openalex   +1 more source

Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 912-922, April 2025.
Abstract Aims Few data are available regarding the role of tricuspid annulus plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP), a measurement of right ventricular to pulmonary artery coupling, in patients with chronic heart failure and left ventricular systolic dysfunction.
Mauro Riccardi   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy